VALEANT PHARMACEUTICALS INTL
COM · CUSIP 91911K102
1
institutional holders
+0 vs Q2 2023
850.0k
shares reported held*
$7.0mreported value*
0 new
0 added
1 reduced
0 sold out
net sold ≈ $622.9k (-75.8k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $8.22.
Trends to Q3 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 1 |
| Q4 2022 | 1 |
| Q1 2023 | 1 |
| Q2 2023 | 1 |
| Q3 2023 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 0 | 0 |
| Q1 2023 | 0 | 1 |
| Q2 2023 | 0 | 0 |
| Q3 2023 | 0 | 1 |
Biggest buyers
| None |
Biggest sellers
| Bruce & Co., Inc. | Reduced | -75.8k |
Holders, Q3 2023
| Manager | Shares | Change |
|---|---|---|
| Bruce & Co., Inc. 2.38% of their portfolio | 850.0k $7.0m | Reduced -75.8k |